



EduraCT Summary Letter

Direct 0045 42443452

Re: "A single-center, double-blind, randomized, 28 day, parallel-group study to evaluate the effect of inhaled ciclesonide 320 mcg twice daily versus placebo on healthcare utilization, disease progression and symptoms in patients with mild-to-moderate COVID-19" [The CIMM-COVID-19 Trial], EduraCT: 2020-002208-37

To whom it may concern,

The clinical trial 2020-002208-37 was, due to regulatory approval delays and changes in the Danish COVID-19 strategy, never initiated. No subjects were recruited, and no results are available for posting.

On behalf Prof. Charlotte Suppli Ulrik

Yours sincerely

Kjell E. J. Håkansson, MD, PhD
Respiratory Research Unit
Copenhagen University Hospital - Hvidovre
kjell@kjell.dk; kjell.erik.julius.haakansson@regionh.dk